{"id":25043,"date":"2025-03-31T11:00:05","date_gmt":"2025-03-31T11:00:05","guid":{"rendered":"https:\/\/medexperts.pro\/?p=25043"},"modified":"2025-03-31T11:25:34","modified_gmt":"2025-03-31T11:25:34","slug":"isomorphic-labs-googles-a-i-drug-business-raises-money-from-thrive","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=25043","title":{"rendered":"Isomorphic Labs, Google\u2019s A.I. Drug Business, Raises Money From Thrive"},"content":{"rendered":"
<\/div>\n

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital as a backer.<\/p>\n

\n
\n
\n

Over the last 12 months, Google\u2019s efforts to use artificial intelligence to accelerate drug design have achieved breakthroughs in mimicking human biology<\/a> and won its top scientists the Nobel Prize in Chemistry<\/a>.<\/p>\n

Now Isomorphic Labs, the division within the software giant meant to develop and commercialize the technology, is taking another big step: raising money from an outside investor.<\/p>\n

Isomorphic plans to announce on Monday that it has raised $600 million, led by Thrive Capital, the venture capital firm that has bet big on A.I. companies including OpenAI. GV, Google\u2019s venture capital arm, and Alphabet, Google\u2019s parent company, also invested.<\/p>\n

The announcement underscores Google\u2019s ambitions for Isomorphic, which was spun out of the company\u2019s DeepMind lab to focus on drugs discovery. It is built on software that DeepMind, a central intelligence lab in London, has developed. That includes AlphaFold, which can predict the structure of millions of proteins and more.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

AlphaFold, which now in its third iteration<\/a> can predict the complex behavior of DNA and RNA, has promised to slash the development time of new drugs. Such is its promise that Demis Hassabis, a co-founder of Isomorphic and DeepMind, and John M. Jumper, a DeepMind researcher, shared half of the Nobel in chemistry last year.<\/p>\n

The goal, according to Mr. Hassabis, is to eventually conduct most of the drug discovery process via computers, rather than traditional labs that require biological materials, strict safety requirements \u2014 and lots of time.<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital as a backer.Over the last 12 months, Google\u2019s efforts to use artificial intelligence to accelerate drug design have achieved breakthroughs in mimicking human biology and won its top scientists the Nobel Prize in Chemistry.Now Isomorphic Labs, the division within the software giant meant to develop and commercialize the technology, is taking another big step: raising money from an outside investor.Isomorphic plans to announce on Monday that it has raised $600 million, led by Thrive Capital, the venture capital firm that has bet big on A.I. companies including OpenAI. GV, Google\u2019s venture capital arm, and Alphabet, Google\u2019s parent company, also invested.The announcement underscores Google\u2019s ambitions for Isomorphic, which was spun out of the company\u2019s DeepMind lab to focus on drugs discovery. It is built on software that DeepMind, a central intelligence lab in London, has developed. That includes AlphaFold, which can predict the structure of millions of proteins and more.AlphaFold, which now in its third iteration can predict the complex behavior of DNA and RNA, has promised to slash the development time of new drugs. Such is its promise that Demis Hassabis, a co-founder of Isomorphic and DeepMind, and John M. Jumper, a DeepMind researcher, shared half of the Nobel in chemistry last year.The goal, according to Mr. Hassabis, is to eventually conduct most of the drug discovery process via computers, rather than traditional labs that require biological materials, strict safety requirements \u2014 and lots of time.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":25045,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-25043","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/25043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25043"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/25043\/revisions"}],"predecessor-version":[{"id":25046,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/25043\/revisions\/25046"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/25045"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}